Serum calcitriol concentrations measured with a new direct automated assay in a large population of adult healthy subjects and in various clinical situations
Serum Calcitriol concentrations Measured with a New Direct Automated Assay in a Large Population of Adult Healthy Subjects and in Various Clinical Situations.pdf
[en] The measurement of calcitriol [1,25(OH2)D], is important for the differential diagnosis of several disorders of calcium/phosphorus metabolism but is time-consuming and tricky. We measured serum calcitriol with a new automated direct assay on the Liaison XL platform in 888 healthy French Caucasian subjects aged 18–89 years, 32 patients with a surgically-proven PHPT, 32 pregnant women at the end of the first and at the end of the third trimester, and 24 dialysis patients before and after one year of supplementationwith vitamin D3 or placebo.
The mean calcitriol concentration (±SD) in the healthy population was 52.9 ± 14.5 ng/L with a 95% CI interval of 29–83.6 ng/L. In PHPT patients, calcitriol concentration was 81.6±29.0 ng/L, 15 of them (46.9%) having a concentration N83.6 ng/L. In pregnant women, calcitriol was 80.4 ± 26.4 ng/L at the end of the first trimester, and 113.1±33.0 ng/L at the end of the third trimester, 12 (37.5%) and 26 (81.3%) of them having a calcitriol concentration
N83.6 ng/L at the first and third trimesters respectively. In 14 dialysis patients, calcitriol was 9.5±7.7 ng/L and rose to 19.3 ng/L after one year of supplementation with 50,000 IU vitamin D3/month. In 10 other dialysis patients, calcitriol was 9.9±2.9 ng/L and remained stable (12.4±3.7 ng/L) after one year of placebo. In conclusion, this new automated calcitriol assay, in addition to presenting excellent analytical performances, gives the expected variations
in patients compared to “normal” values obtained in an extensive reference population
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
Souberbielle, Jean-Claude
CAVALIER, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Chimie clinique
DELANAYE, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
Massart, C
Brailly-Tabard, S
Cormier, C
Borderie, D
Benachi, A
Chanson, P
Language :
English
Title :
Serum calcitriol concentrations measured with a new direct automated assay in a large population of adult healthy subjects and in various clinical situations
Holick M. Vitamin D deficiency. N. Engl. J. Med. 2007, 357:266-281.
Christakos S., Hewison M., Gardner D., Wagner C., Sergeev I., Rutten E., Pittas A., Boland R., Ferrucci L., Bikle D. Vitamin D: beyond bone. Ann. N. Y. Acad. Sci. 2013, 1287:45-58.
Holick M., Binkley N., Bischoff-Ferrari H., Gordon C., Hanley D., Heaney R., et al. Evaluation, treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96:1911-1930.
Kallas M., Green F., Hewison M., White C., Kline G. Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review. J. Clin. Endocrinol. Metab. 2010, 95:3111-3117.
Malloy P.J., Feldman D. Genetic disorders and defects in vitamin D action. Endocrinol. Metab. Clin. N. Am. 2010, 39:333-346.
Hollis B., Johnson D., Hulsey T., et al. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J. Bone Miner. Res. 2011, 26:2341-2357.
Patron P., Gardin J.P., Paillard M. Renal mass and reserve of vitamin D: determinants in primary hyperparathyroidism. Kidney Int. 1987, 31:1174-1180.
Dusso A., Brown A.J., Slatopolsky E. Vitamin D. Am. J. Physiol. Ren. Physiol. 2005, 289:F8-F28.
Lund B., Sorensen O.H., Lund J., Bishop J., Norman A. Vitamin D metabolism in hypoparathyroidism. J. Clin. Endocrinol. Metab. 1980, 51:606-610.
Hollis B., Kamerud J., Kurkowsky A., Beaulieu J., Napoli J.L. Quantification of circulating 1,25 dihydroxyvitamin D by radio-immunoassay with an 125I-labeled tracer. Clin. Chem. 1996, 45:586-592.
Frazer W., Durhan B., Berry J., Mawer E. Measurement of plasma 1,25 dihydroxyvitamin D using a novel immunoextraction technique and immunoassay with iodine labelled vitamin D tracer. Ann. Clin. Biochem. 1997, 34:632-637.
Casetta B., Jans I., Billen D., Bouillon R. Development of a method for the quantification of 1α,25(OH)2-vitamin D3 in serum by liquid chromatography-tandem mass spectrometry without derivatization. Eur. J. Mass Spectrom. 2010, 16:81-89.
Stratham F., Laha T., Hoofnagle A. Quantification of 1α,25-dihydroxy-vitamin D by immunoextraction and liquid chromatography-tandem mass spectrometry. Eur. J. Mass Spectrom. 2011, 57:1279-1285.
Van Helden J., Weiskirchen R. Experience with the first fully automated chemiluminescence immunoassay for the quantification of 1α,25-dihydroxy-vitamin D. Clin. Chem. Lab. Med. 2015, 53:761-770.
Koumakis E., Souberbielle J.C., Sarfati E., Meunier M., Maury E., Gallimard E., et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2013, 98:3213-3220.
Delanaye P., Weekers L., Warling X., Moonen M., Smelten N., Medart L., Krzesinski J.M., Cavalier E. Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study. Nephrol. Dial. Transplant. 2013, 28:1779-1786.
Horn P., Feng L., Li Y., Pesce A. Effect of outliers and nonhealthy individuals on reference interval estimation. Clin. Chem. 2001, 2137-3145.
Davies M., Adams P.H., Berry J.L., Lumb G.A., Klimiuk P.S., Mawer E.B., Wain D. Familial hypocalciuric hypercalcemia - observation on vitamin D metabolism and parathyroid function. Acta Endocrinol. (Copenh) 1983, 104:2010-2215.
Law W.M., Bollman S., Kumar R., Heath H. Vitamin D metabolism in familial benign hypercalcemia (hypocalciuric hypercalcemia) differs from that in hyperparathyroidism. J. Clin. Endocrinol. Metab. 1984, 58:744-747.
Christensen S.E., Nissen P., Vestergaard P., Heickendorff L., Rejnmark L., Brixen K., Mosekilde L. Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism. Eur. J. Endocrinol. 2008, 159:719-727.
Moosgard B., Christensen S.E., Vestergaard P., Heickendorff L., Christiansen P., Mosekilde L. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin. Endocrinol. 2008, 68:707-715.
Lalor B., Mawer E.B., Davies M., Lumb G.A., Hunt L., Adams P.H. Determinants of the serum concentration of 1,25-dihydroxyvitamin D in primary hyperparathyroidism. Clin. Sci. 1989, 76:81-86.
-Thakker RV, Fraher LJ, Adami S, Karnali R, O'Riordan JL. Circulating concentrations of 1,25-dihydroxyvitamin D3 in patients with primary hyperparathyroidism. Bone Miner. 1986; 1: 137-144.
Bergenfelz A., Lindegard B., Ahren B. Biochemical variables associated with bone density in patients with primary hyperparathyroidism. Eur. J. Surg. 1992, 158:473-476.
Nordenström E., Westerdahl J., Bergenfelz A. Recovery of bone mineral density in 126 patients after surgery for primary hyperparathyroidism. World J. Surg. 2004, 28:502-507.
Kumar R., Cohen W.R., Silva P., Epstein F.H. Elevated 1,25-dihydroxyvitamin D plasma levels in normal human pregnancy and lactation. J. Clin. Invest. 1979, 63:342-344.
Reddy G.S., Norman A.W., Willis D.M., Goltzman D., Guyda H., Solomon S., Philips D.R., Bishop J.E., Mayer E. Regulation of vitamin D metabolism in normal human pregnancy. J. Clin. Endocrinol. Metab. 1983, 56:363-370.
Moller U.K., Streym S., Mosekilde L., Heickendorff L., Flyvbjerg A., Frystyk J., Jensen L.T., Rejnmark L. Changes in calciotropic hormones, bone markers and insulin-like growth factor I (IGF-I) during pregnancy and postpartum: a controlled cohort study. Osteoporos. Int. 2013, 24:1307-1320.
Whitsett J., Ho M., Tsang R., Norman E., Adams K. Synthesis of 1,25-dihydroxyvitamin D3 by human placenta in vitro. J. Clin. Endocrinol. Metab. 1981, 53:484-488.
Halloran B.P., Schaefer P., Lifschitz M., Levens M., Goldsmith R.S. Plasma vitamin D metabolite concentrations in chronic renal failure: effects of oral administration of 25 hydroxyvitamin D3. J. Clin. Endocrinol. Metab. 1984, 59:1063-1069.
Jean G., Terrat J.C., Vanel T., et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6months of 25-hydroxycholecalciferol treatment. Nephron Clin. Pract. 2008, 110:c58-c65.
Jean G., Souberbielle J.C., Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol. Dial. Transplant. 2009, 24:3799-3805.
Barbour G.L., Coburn J.W., Slatopolsky E., Norman A.W., Horst R.L. Hypercalcemia in an anephric patient with sarcoidosis: evidence for extra-renal generation of 1,25-dihydroxyvitamin D. N. Engl. J. Med. 1981, 305:440-443.
Lambert P.W., Stern P.H., Avioli R.C., Brachet N.C., Turner R.T., Greene A., Fu I., Bell N.H. Evidence for extra-renal production of 1-alpha-hydroxylase vitamin D in man. J. Clin. Invest. 1982, 69:722-725.
Dusso A., Lopez-Hilker S., Rapp N., Slatopolsky E. Extra-renal production of calcitriol in chronic renal failure. Kidney Int. 1988, 34:368-375.
